Published in Br J Pharmacol on January 01, 2001
Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol (2002) 1.04
CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol (2004) 1.02
Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction--a novel mechanism for maintaining vascular function. J Hematol Oncol (2014) 0.95
Endothelin. Pharmacol Rev (2016) 0.95
Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br J Pharmacol (2001) 0.89
Nitric oxide blunts the endothelin-mediated pulmonary vasoconstriction in exercising swine. J Physiol (2005) 0.80
Exercise limits the production of endothelin in the coronary vasculature. Am J Physiol Heart Circ Physiol (2011) 0.80
Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction. J Physiol (2007) 0.77
Nitric oxide modulates renal vasoconstrictor effect of endothelin-1 in conscious lambs. Pediatr Nephrol (2005) 0.76
The effect of ozone on blood pressure in DOCA-salt-induced hypertensive rats. Int J Clin Exp Med (2015) 0.75
Conceptual approaches for treatment of phosgene inhalation-induced lung injury. Toxicol Lett (2015) 0.75
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol (1989) 6.87
Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ Res (1983) 6.42
Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science (1998) 4.58
Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron (1992) 2.54
Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci (2000) 2.24
cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1996) 2.17
Spontaneous liberation of nitric oxide cannot account for in vitro vascular relaxation by S-nitrosothiols. J Pharmacol Exp Ther (1990) 2.10
Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet (1990) 2.04
Nitric oxide in septic shock. Biochim Biophys Acta (1999) 1.83
A comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry. Anal Biochem (1999) 1.76
Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation (1999) 1.71
Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem (1992) 1.69
Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol (1989) 1.57
Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res (1993) 1.56
Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol (1999) 1.55
Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med (1997) 1.50
Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol (1995) 1.48
ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol (1995) 1.48
Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation (1996) 1.47
Plasma endothelin in chronic heart failure. Circulation (1992) 1.47
The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol (1999) 1.42
Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res (1990) 1.37
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 1.21
Evidence that different mechanisms underlie smooth muscle relaxation to nitric oxide and nitric oxide donors in the rabbit isolated carotid artery. Br J Pharmacol (1998) 1.06
Nitric oxide activates or inhibits skeletal muscle ryanodine receptors depending on its concentration, membrane potential and ligand binding. J Membr Biol (2000) 1.05
Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res (1996) 1.04
Nitric oxide/nucleophile complexes: a unique class of nitric oxide-based vasodilators. J Cardiovasc Pharmacol (1993) 0.99
Endothelin- and neuropeptide Y-induced vasoconstriction of human epicardial coronary arteries in vitro. Br J Pharmacol (1989) 0.99
Termination of endothelin signaling: role of nitric oxide. J Cell Physiol (1994) 0.99
Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide. Br J Pharmacol (1998) 0.96
Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase. Biochem J (1997) 0.96
The quasi-irreversible nature of endothelin binding and G protein-linked signaling in cardiac myocytes. J Pharmacol Exp Ther (1997) 0.95
Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin. J Cardiovasc Pharmacol (1998) 0.95
Nitric oxide synthase activity endogenously modulates NMDA receptors. J Neurochem (1993) 0.94
Endothelin receptors in human coronary artery and aorta. Br J Pharmacol (1996) 0.92
Activation and inhibition of purified skeletal muscle calcium release channel by NO donors in single channel current recordings. Biochim Biophys Acta (1999) 0.92
Oxygen and oxidation promote the release of nitric oxide from sydnonimines. J Cardiovasc Pharmacol (1989) 0.91
Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol (1999) 0.89
Modulation of angiotensin-converting enzyme by nitric oxide. Br J Pharmacol (1998) 0.89
Nitric oxide modulates NMDA-induced increases in intracellular Ca2+ in cultured rat forebrain neurons. Brain Res (1992) 0.87
Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors. J Pharmacol Exp Ther (1997) 0.86
ETA receptors predominate in the human vasculature and mediate constriction. J Cardiovasc Pharmacol (1995) 0.85
The effect of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide. Brain Res (1998) 0.84
Inhibition of glucocorticoid receptor binding by nitric oxide. Mol Pharmacol (1999) 0.84
Plasma endothelin levels are increased during septic shock. Crit Care Med (1992) 0.83
Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock. Circulation (1999) 0.82
Nitric oxide inhibition of the rat olfactory cyclic nucleotide-gated cation channel. J Membr Biol (1998) 0.80
Pathologic role of endothelin-1 in septic shock. J Cardiovasc Pharmacol (1998) 0.80
Evidence that humans produce less nitric oxide than experimental animals in septic shock. Crit Care Med (1998) 0.79
Interactions between nitrogen oxide-containing compounds and peripheral benzodiazepine receptors. FEBS Lett (1990) 0.78
Novel nitric oxide donors reverse endothelin-1-mediated constriction in human blood vessels. J Cardiovasc Pharmacol (2000) 0.77
Suppression of neuropeptide Y1 receptor function in SK-N-MC cells by nitric oxide. Am J Physiol (1997) 0.77
Extracellular cysteine residues 174 and 255 are essential for active expression of human endothelin receptor ETB in Escherichia coli. J Cardiovasc Pharmacol (1993) 0.77
Pharmacological characterisation of endothelium-dependent relaxation in human radial artery: comparison with internal thoracic artery. Cardiovasc Res (1999) 0.77
Creation of a functional S-nitrosylation site in vitro by single point mutation. FEBS Lett (1999) 0.77
Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved. Eur J Cell Biol (1994) 0.76
Nitric oxide does not modulate kainate receptor binding in human brain. Neurosci Lett (1997) 0.76
Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation (2002) 4.43
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol (2000) 1.78
Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res (1993) 1.56
ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol (1995) 1.48
[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol (2001) 1.40
Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol (2011) 1.29
Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int (1993) 1.22
Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart. Br J Pharmacol (1992) 1.17
Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br J Pharmacol (1994) 1.15
Endothelin-1 mRNA is widely expressed in porcine and human tissues. J Clin Invest (1990) 1.13
[125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol (2001) 1.11
Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. Br J Pharmacol (2007) 1.11
Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol (2001) 1.10
Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res (1996) 1.04
Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. Br J Pharmacol (1994) 1.01
Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle. J Clin Endocrinol Metab (1992) 1.00
Effect of in vivo fetal infusion of dexamethasone at 0.75 GA on fetal ovine resistance artery responses to ET-1. Am J Physiol Regul Integr Comp Physiol (2001) 1.00
Secretory pathways in endothelin synthesis. Br J Pharmacol (1999) 0.98
Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme. Circ Res (1998) 0.97
Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens (1992) 0.95
Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin. J Cardiovasc Pharmacol (1998) 0.95
Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol (2001) 0.93
Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis (2009) 0.93
Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br J Pharmacol (2009) 0.93
Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol (1998) 0.93
Endothelin receptors in human coronary artery and aorta. Br J Pharmacol (1996) 0.92
Endothelin converting enzyme (ECE) activity in human vascular smooth muscle. Br J Pharmacol (1997) 0.90
Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells. Br J Pharmacol (1995) 0.89
Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br J Pharmacol (2001) 0.89
Endothelin receptor subtypes and their functional relevance in human small coronary arteries. Br J Pharmacol (1998) 0.89
Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart. Br J Pharmacol (1996) 0.89
The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol (1996) 0.89
Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution. Biochem Biophys Res Commun (1993) 0.88
Evidence for intracellular endothelin-converting enzyme-2 expression in cultured human vascular endothelial cells. Circ Res (1999) 0.88
Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol (2010) 0.88
Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res (2000) 0.87
Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated. J Cardiovasc Pharmacol (1993) 0.87
A quantitative 'in-situ' hybridization method using computer-assisted image analysis. Validation and measurement of atrial-natriuretic-factor mRNA in the rat heart. Biochem J (1989) 0.87
Blockade and reversal of endothelin-induced constriction in pial arteries from human brain. Stroke (1999) 0.87
Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro. Br J Pharmacol (2001) 0.86
Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol (1995) 0.86
Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors. J Pharmacol Exp Ther (1997) 0.86
Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments. Br J Pharmacol (1996) 0.86
Characterization of the binding of endothelin ETB selective ligands in human and rat heart. Br J Pharmacol (1996) 0.85
Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol (2014) 0.85
Expression of endothelin peptides and mRNA in the human heart. Clin Sci (Lond) (1996) 0.85
Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol (2002) 0.85
Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells. Br J Pharmacol (1995) 0.85
Quantification of mRNA in human tissue using fluorescent nested reverse-transcriptase polymerase chain reaction. Anal Biochem (1994) 0.84
Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues. Hum Reprod (1991) 0.84
Endothelin expression in the uterus. J Steroid Biochem Mol Biol (1995) 0.84
Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol (1999) 0.84
Localization of endothelin peptides in human kidney. Kidney Int (1996) 0.84
Localization of endothelin receptors in human uterus throughout the menstrual cycle. Mol Hum Reprod (1996) 0.84
Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br J Pharmacol (1995) 0.83
Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Neurosurgery (1998) 0.83
Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas. J Cardiovasc Pharmacol (1995) 0.83
Endothelin: progress in pharmacology and physiology. Trends Pharmacol Sci (1993) 0.83
Differential distribution of endothelin receptor subtypes in placentae from normal and growth-restricted pregnancies. Placenta (1997) 0.82
Relative contribution of endothelin A and endothelin B receptors to vasoconstriction in small arteries from human heart and brain. J Cardiovasc Pharmacol (1998) 0.82
Human kidney: endothelin isoforms detected by HPLC with radioimmunoassay and receptor subtypes detected using ligands BQ123 and BQ3020. J Cardiovasc Pharmacol (1993) 0.82
Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells: measurement by two-site enzyme-linked immunosorbent assays. Clin Sci (Lond) (1994) 0.82
ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242. J Endocrinol (1995) 0.81
Maternal dexamethasone increases endothelin-1 sensitivity and endothelin a receptor expression in ovine foetal placental arteries. Placenta (2003) 0.81
Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmacol (1992) 0.81
Endothelin-A-receptors in human aorta and pulmonary arteries are downregulated in patients with cardiovascular disease: an adaptive response to increased levels of endothelin-1? J Cardiovasc Pharmacol (2000) 0.81
Regulation of endothelin receptor expression in vascular smooth-muscle cells. J Cardiovasc Pharmacol (1995) 0.81
Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. J Hypertens (1994) 0.81
Endothelin-like immunoreactivity in human endometrium. J Reprod Fertil (1992) 0.81
Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. Br J Pharmacol (1998) 0.80
Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation. Br J Pharmacol (2006) 0.80
Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium. J Reprod Fertil (1993) 0.80
The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis (1990) 0.79
No alteration in vasoconstrictor endothelin-B-receptor density or function in human coronary artery disease. J Cardiovasc Pharmacol (2000) 0.79
Localization and endogenous concentration of endothelin-like immunoreactivity in human placenta. J Endocrinol (1991) 0.78
Endothelin-2 mRNA splice variants detected by RT-PCR in cultured human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol (1993) 0.78
Measurement of C-terminal fragment of big endothelin-1: a novel method for assessing the generation of endothelin-1 in humans. J Cardiovasc Pharmacol (1995) 0.78
Delineation of endothelin receptors in human left ventricular smooth-muscle cells. J Cardiovasc Pharmacol (1995) 0.78
Changes in ET(A)-, AT1- and AT2-receptors in the phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries. J Cardiovasc Pharmacol (2000) 0.78
Syntheses of the first endothelin-A- and -B-selective radioligands for positron emission tomography. J Cardiovasc Pharmacol (2000) 0.77
Endothelin peptide and converting enzymes in human endothelium. J Cardiovasc Pharmacol (1998) 0.77
Novel nitric oxide donors reverse endothelin-1-mediated constriction in human blood vessels. J Cardiovasc Pharmacol (2000) 0.77
Endothelin and the human kidney: a potential target for new drugs. Nephrol Dial Transplant (1994) 0.77
PD156707: a potent antagonist of endothelin-1 in human diseased coronary arteries and vein grafts. J Cardiovasc Pharmacol (1998) 0.77
Distribution of endothelin receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol (1995) 0.77
Biogenic amines in the brain of the honeybee, Apis mellifera. Cell Tissue Res (1983) 0.77
The haemodynamic effects of iodinated water soluble radiographic contrast media: a review. Eur J Radiol (1998) 0.76
Atrial natriuretic factor mRNA and binding sites in the adrenal gland. Biochem J (1990) 0.76
Comparative quantification of endothelin receptor mRNA in human kidney: new tools for direct investigation of human tissue. J Cardiovasc Pharmacol (1995) 0.76
Endothelin-1 stimulates prostaglandin F2 alpha release from human endometrium. Prostaglandins Leukot Essent Fatty Acids (1991) 0.76
Characterization of peptide and nonpeptide antagonists in human kidney. J Cardiovasc Pharmacol (1995) 0.76
In vitro enzymatic processing of radiolabelled big ET-1 in human kidney. Biochem Pharmacol (1998) 0.76
Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b. Brain Res (1992) 0.76
Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography. J Cardiovasc Pharmacol (1997) 0.76
Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139. J Cardiovasc Pharmacol (1995) 0.76
Characterization of site-directed antisera against endothelin-converting enzymes. J Cardiovasc Pharmacol (1998) 0.75
Autoradiographic study of endothelin receptors in human cerebral arteries. J Cardiovasc Pharmacol (1995) 0.75
Sex-related differences in the concentration of Met-enkephalin-like immunoreactivity in the nervous system of an insect, Schistocerca gregaria, revealed by radioimmunoassay. Brain Res (1986) 0.75